期刊文献+

表达人CD40配体的重组腺病毒载体的构建 被引量:1

Construction of the Recombinant Adenovirus Vector Expressing Human CD40 Ligand Gene
下载PDF
导出
摘要 目的构建含有hCD40L基因的重组腺病毒载体,为其在动物模型体内表达和肿瘤基因治疗提供基础。方法用XhoⅠ、SwaⅠ双酶切质粒pORF_hCD40L,回收1 900 bp基因片段并定向克隆插入穿梭质粒pShuttle中XhoⅠ、EcoRⅤ双酶切位点,得到重组质粒pShuttle_hCD40L。经PmeI酶切与腺病毒骨架质粒pAdEasy_1共转化BJ5183细菌,同源重组后用选择培养基筛选阳性克隆,提取质粒PacI酶切线性化后用脂质体介导转染293细胞。酶切分析和PCR鉴定重组的腺病毒。结果酶切分析、PCR验证表明,hCD40L基因成功克隆到腺病毒pAdEasy_1载体中。结论成功构建表达hCD40L基因的重组腺病毒载体,为进一步研究其在哺乳动物内表达及基因治疗提供了基础。 Objective To construct a recombinant adenovims vector expressing hCD40L gene and explore it in the use of antitumor gene therapy.Methods 1 900 bp gene fragment was obtained form plasmid pORF-hCD40L by Xho Ⅰ / Swa Ⅰ cutting and then cloned directionaUy into the pShuttle plasmid, finally, the resultant plasmid was digested by restriction endonnuclease PmeI and subsequently cotransformtion into BJ5183 cells with the adenoviral backbone pAdEasy-1 to obtain the homologous recombinant and then the recombinant was packaged in the 293 cells. Some methods such as PCR and endonulease digestion were employed to identify the recombinant adenovims. Results The evidences of endonulease digestion and PCR analysis confirmed that recombinant hCD10L gene was correctly inserted into adenovims vector. Conelusion The adenoviral vector which expressed hCD40L gene was constructed. It provides an experimental basis for studies on it expression in the mammalian ceils and in tumor gene therapy.
出处 《华西口腔医学杂志》 CAS CSCD 北大核心 2005年第6期534-536,共3页 West China Journal of Stomatology
基金 国家自然科学基金资助项目(3013026)
关键词 hCD40L基因 腺病毒载体 DNA同源重组 基因治疗 hCD40L gene adenovirus vector DNA homologous recombination gene therapy
  • 相关文献

参考文献11

  • 1Schonbeck U,Libby P.The CD40/CD154 receptor/ligand dyad[J].Cell Mol Life Sci,2001,58(1):4-43.
  • 2Pandori M,Hobson D,Sano T.Adenovirus-microbead conjugates possess enhanced infectivity:A new strategy for localized gene delivery[J].Virology,2002,299(2):204-212.
  • 3Nasz I,Adam E.Recombinant adenovirus vectors for gene therapy and clinical trials[ J ].Acta Microbiol Immunol Hung,2001,48 (3-4):323-348.
  • 4Adam E,Nasz I.Adenovirus vectors and their clinical application in gene therapy[J].Orv Hetil,2001,142(38):2061-2070.
  • 5Tong-chuan HE,Shibin Z,Luis T.A simplified system for generating recombinant adenoviruses[J].Proc Natl Acad Sci USA,1998,95(5):2059-2514.
  • 6Briones J,Timmerman J,Levy R.In vivo antitumor effect of CD4OLtransduced tumor cells as a vaccine for B-cell lymphoma[J].Cancer Res,2002,62 (11):3195-3199.
  • 7Loskog A,Totterman TH,Bohle A.In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154[J].Cancer Gere Ther,2002,9(10):846-853.
  • 8崔巍,樊英,李龙芸.CD40/CD40L与肿瘤的关系[J].中华医学全科杂志,2003,2(6):55-57. 被引量:1
  • 9Kikuchi T,Crystal RG.Anti-tumor immnunity induced byin vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells[J].Hum Gene Ther,1999,10(8):1375-1387.
  • 10Sun Y,Pend D,LecandaJ.In vivo gene transfer of CD40 ligand into corlon cancer cells induces local production of cytokines and chemokines.Tumor eradication and protective antitumor immunity[J].Gene Ther,2000,7 (17):1467-1476.

同被引文献12

  • 1Tanja Hakkarainen, Akseli Hemminki, Alexander V. Pereboev et al. CD40 Is Expressed on Ovarian Cancer Cells and Can Be Utilized for Targeting Adenoviruses [J]. Clinical Cancer Research, 2003, 9 : 619-624.
  • 2Jamal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004 CA [J]. Cancer J Clin, 2004, 54 (1): 8-29.
  • 3Rosenberg SA. Progress in human tumour immunology and immunotherapy[J]. Nature, 2001, 411: 380-38.
  • 4Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy [J]. Nat Immunol, 2001, 2 (4) : 293-299.
  • 5Pandori M, Hobson D, Sano T. Adenovirus-microbead conjugates possess enhanced infectivity: a new strategy for localized gene delivery[J]. Virology, 2002, 299: 204-212.
  • 6Clark LB, Foy TM, Noene RJ, et al. CD40 and its ligand[J]. Adv Immunol, 1996, 63: 43-78.
  • 7Vestal RE, WingettDG, Knight LK, et al. Expression of CD40 in breast, colon, lung and ovarian tumors[J]. Proc AM A ssocCancer Res, 1997, 38: 1456-1550.
  • 8Ghammnde S, Hylander BL, Otlazoglu E, et al. Recombinant CD40 ligand therapy has significant antitumor effects on CD40- positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin [J]. Cancer Res, 2001, 61: 7556-7562.
  • 9Pulten SS, Miller HG, Everdeen DS, et al. CD40- tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomefization [J]. Biochemistry, 1998, 37: 11836- 11845.
  • 10Frketa D, Lin JT, Quezada SA, et al. Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice [J]. J Immunother, 2003, 26: 72-84.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部